about
Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations.Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease miceItalian Huntington disease patients--data and tissue bank.Tractography of the corpus callosum in Huntington's disease.DNA instability in replicating Huntington's disease lymphoblastsChanges of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington diseaseDefective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.Onset and pre-onset studies to define the Huntington's disease natural history.Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations.Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1.ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations.Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease.Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation.Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal ModelsMotor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) miceHighly disabling cerebellar presentation in Huntington disease.Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.The Corticospinal Tract in Huntington's Disease.The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea.MRI measures of corpus callosum iron and myelin in early Huntington's disease.Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease.Glycosphingolipid metabolic reprogramming drives neural differentiation.De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease.Cavernous angiomas of the nervous system in Italy: clinical and genetic study
P50
Q24532170-859A1954-15AB-4C4A-A0B0-C069CE183BCDQ30506469-89AF69BE-F3F1-4620-AFD8-2FDEFD7B7597Q30883477-6D10167F-0E3C-4A67-8AD1-A58D94E3D9F9Q31137452-96EDEFAB-42FC-42D3-8D8B-A6FE61D56465Q33408394-16F6DF5D-FB9A-499C-8D97-DC73AD0F6A73Q33644718-F6B394A0-573A-4A1C-96AC-ACDFB97E9998Q33902931-D1FEA78A-B894-4EA1-958D-A13D200E30DDQ34181024-04047069-001F-49AD-B93D-6399D68881F1Q34446550-54B2A453-F9B6-4371-99A6-12F8D38E7E4FQ34620113-A8C9C3F1-7163-438A-B93F-EB4966D8EF8BQ35107991-B4AC71E9-F6A8-41A9-B7C1-1AD116B05386Q38766477-DC5B0C2A-4997-4B14-84F3-8798A2849587Q38861728-B78104D5-5EC6-4D49-9F52-CC569E898A88Q38954727-AB58FC47-4082-4AAE-AA3E-324AC078D142Q39049796-568BFE79-CE22-4298-86DB-AA7A56B93B18Q39726453-CF991CA6-EA43-4B7F-873E-1A15ED356C3BQ39960832-067AF73F-C3E9-492A-9ADA-11963AA5EEACQ40245975-1DDB852D-ABA4-47F9-AA11-9C43E7F7585DQ40351019-04D900E3-4FEA-4078-A7A5-E59433E721DEQ41340916-BE25C782-B37C-464E-A444-67E5B1037DB2Q41842714-B5E6CEB0-08D5-4BC8-BAA1-396B845B77C4Q45289403-9881282F-0254-4690-A796-51C472BD58E3Q45295362-462EFC7C-C718-4137-A80C-0473B4F7F784Q45298673-F217019C-1913-46BC-AC45-C292269548D5Q45298788-0B959D51-5682-48BF-85C7-3678FAA015E5Q45299568-2CAB7130-5CF3-4C8C-9689-C536F3329C09Q45302615-877EA2EC-D375-43F0-AEA5-BF824C2254C4Q47098894-CD810A5F-3214-4A73-A825-CEBABFEECB13Q47251188-879EAA82-DAF6-4AD9-9209-EAC66C9E65F9Q47273613-C0D77D1F-B262-4B03-88E2-E24FD7B1CBDAQ57405918-80DA5730-A185-4E4C-A260-2F9F684BE805
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vittorio Maglione
@en
Vittorio Maglione
@es
Vittorio Maglione
@nl
Vittorio Maglione
@sl
type
label
Vittorio Maglione
@en
Vittorio Maglione
@es
Vittorio Maglione
@nl
Vittorio Maglione
@sl
prefLabel
Vittorio Maglione
@en
Vittorio Maglione
@es
Vittorio Maglione
@nl
Vittorio Maglione
@sl
P106
P1153
6508370268
P21
P2798
P31
P496
0000-0002-6906-7372